OncLive
LightNews LightNews
banner
onclive.bsky.social
OncLive
@onclive.bsky.social
950 followers 140 following 2.6K posts
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Posts Replies Media Videos
onclive.bsky.social
Saving Lives From Lymphoma: The Life and Career of Franco Cavalli, MD #lymsm #oncology www.onclive.com/view/saving-...
Saving Lives From Lymphoma: The Life and Career of Franco Cavalli, MD | OncLive
Franco Cavalli, MD, has dedicated his life to treating patients, developing drugs, and bringing higher quality cancer care to areas in need of improvement
www.onclive.com
December 31, 2025 at 1:12 PM
onclive.bsky.social
ICYMI 🚨: The FDA has approved narsoplimab-wuug (Yartemlea) injection for the treatment of adults and children aged 2 years and older with hematopoietic stem cell transplant–associated thrombotic microangiopathy.
Click the link to learn more 🔗 www.onclive.com/view/fda-app... #oncology
FDA Approves Narsoplimab for Hematopoietic Stem Cell Transplant–Associated Thrombotic Microangiopathy | OncLive
The FDA has approved narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
www.onclive.com
December 30, 2025 at 11:22 PM
onclive.bsky.social
Prevention Matters: Offit and the Birth of Cancer Genetics @mskcancercenter.bsky.social #GiantsofCancerCare #oncology

www.onclive.com/view/prevent...
Prevention Matters: Offit and the Birth of Cancer Genetics | OncLive
Kenneth Offit, MD, MPH, is a pioneering cancer geneticist whose groundbreaking work has shaped how hereditary cancer is understood, prevented, and managed.
www.onclive.com
December 30, 2025 at 5:46 PM
onclive.bsky.social
Faster Approach Determines Brain Cancer Treatment Is Working @umich.edu #btsm #oncology
www.onclive.com/view/faster-...
Faster Approach Determines Brain Cancer Treatment Is Working | OncLive
Researchers at Northwestern Medicine have developed a new and faster approach to determine if a treatment for the brain cancer glioblastoma is working.
www.onclive.com
December 30, 2025 at 4:02 PM
onclive.bsky.social
Real-World Elranatamab Is Active in Relapsed/Refractory Multiple Myeloma #oncology #myeloma
www.onclive.com/view/real-wo...
Real-World Elranatamab Is Active in Relapsed/Refractory Multiple Myeloma | OncLive
Real-world elranatamab led to higher response rates despite less favorable baseline characteristics vs real-world teclistamab in R/R multiple myeloma.
www.onclive.com
December 30, 2025 at 2:02 PM
onclive.bsky.social
Mobile Health Intervention Improves QOL in AYA Breast Cancer Survivors #oncology #bcsm
www.onclive.com/view/mobile-...
Mobile Health Intervention Improves QOL in AYA Breast Cancer Survivors | OncLive
A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.
www.onclive.com
December 29, 2025 at 5:21 PM
onclive.bsky.social
Epcoritamab, Glofitamab Are Associated With Early Progression in R/R LBCL
@ash.hematology.org #ASH25 #lymsm #oncology
www.onclive.com/view/epcorit...
Epcoritamab, Glofitamab Are Associated With Early Progression in R/R LBCL | OncLive
Glofitamab and epcoritamab were both associated with early disease progression in relapsed/refractory large B-cell lymphoma.
www.onclive.com
December 29, 2025 at 4:01 PM
onclive.bsky.social
Palazestrant Monotherapy Moves Into Phase 3 Examination in ER+, HER2– Breast Cancer
#bcsm #oncology
www.onclive.com/view/palazes...
Palazestrant Monotherapy Moves Into Phase 3 Examination in ER+, HER2– Breast Cancer | OncLive
Heather McArthur, MD, MPH, FASCO, elaborates on clinical trial data for palazestrant monotherapy in breast cancers.
www.onclive.com
December 29, 2025 at 3:59 PM
onclive.bsky.social
The Movement of Medicine: The Mindful Path of an MPN Giant @mayocliniccancer.bsky.social #oncology #hematology #MPN
www.onclive.com/view/the-mov...
The Movement of Medicine: The Mindful Path of an MPN Giant | OncLive
Ayalew Tefferi, MD, tirelessly advances medicine, driven by a philosophy that physical and intellectual journeys are one.
www.onclive.com
December 26, 2025 at 3:12 PM
onclive.bsky.social
Redefining How to Communicate Treatment Options May Facilitate Equitable Clinical Trial Enrollment #oncology
www.onclive.com/view/redefin...
Redefining How to Communicate Treatment Options May Facilitate Equitable Clinical Trial Enrollment | OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
December 26, 2025 at 1:51 PM
onclive.bsky.social
Bezuclastinib Reverses Key Bone Marrow Pathology in Nonadvanced Systemic Mastocytosis
@ash.hematology.org #ASH25 #oncology
www.onclive.com/view/bezucla...
Bezuclastinib Reverses Key Bone Marrow Pathology in Nonadvanced Systemic Mastocytosis | OncLive
Bezuclastinib normalized key bone marrow pathology in nonadvanced systemic mastocytosis.
www.onclive.com
December 23, 2025 at 9:23 PM
onclive.bsky.social
Ceralasertib Plus Durvalumab Misses OS End Point in Previously Treated Advanced NSCLC
#lcsm #oncology
www.onclive.com/view/ceralas...
Ceralasertib Plus Durvalumab Misses OS End Point in Previously Treated Advanced NSCLC | OncLive
Ceralasertib plus durvalumab did not improve overall survival vs docetaxel in previously treated advanced non–small cell lung cancer.
www.onclive.com
December 23, 2025 at 3:40 PM
onclive.bsky.social
Toxicity Considerations Drive Treatment Strategies in the New Era of NSCLC Therapy #oncology #lcsm #nsclc
www.onclive.com/view/toxicit...
Toxicity Considerations Drive Treatment Strategies in the New Era of NSCLC Therapy | OncLive
Balazs Halmos, MD, MS, and Jamie E. Chaft, MD, discuss how safety considerations contribute to treatment selection in NSCLC.
www.onclive.com
December 23, 2025 at 3:06 PM
onclive.bsky.social
Avapritinib Yields Sustained Symptom Reduction and Safety in Indolent SM @huntsmancancer.bsky.social @ash.hematology.org #ASH25 #hematology
www.onclive.com/view/avaprit...
Avapritinib Yields Sustained Symptom Reduction and Safety in Indolent SM | OncLive
Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.
www.onclive.com
December 23, 2025 at 2:59 PM
onclive.bsky.social
Orca-T With Reduced Intensity Conditioning Is Safe and Feasible in Hematologic Malignancies

www.onclive.com/view/orca-t-...
Orca-T With Reduced Intensity Conditioning Is Safe and Feasible in Hematologic Malignancies | OncLive
Orca-T given with reduced intensity conditioning led to robust myeloid/T-cell engraftment and low rates of acute GVHD in hematologic malignancies.
www.onclive.com
December 22, 2025 at 9:22 PM
onclive.bsky.social
Transarterial Microperfusion for Pancreatic Adenocarcinoma: A New Way of Addressing an Old Problem @hackensackmeridianhealth.org #oncology #pcsm
www.onclive.com/view/trans-a...
Transarterial Microperfusion for Pancreatic Adenocarcinoma: A New Way of Addressing an Old Problem | OncLive
Pancreatic ductal adenocarcinoma remains highly lethal due to late presentation, treatment resistance, and limited drug delivery with standard systemic therapies.
www.onclive.com
December 22, 2025 at 8:46 PM
onclive.bsky.social
FDA Gives Breakthrough Therapy Designation to Post-Neoadjuvant T-DXd for HER2+ Early #BreastCancer #oncology

www.onclive.com/view/fda-giv...
FDA Gives Breakthrough Therapy Designation to Post-Neoadjuvant T-DXd for HER2+ Early Breast Cancer | OncLive
Post-neoadjuvant T-DXd has received breakthrough therapy designation from the FDA for HER2-positive early breast cancer with residual invasive disease.
www.onclive.com
December 22, 2025 at 6:45 PM
onclive.bsky.social
Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC #oncology #lcsm #nsclc
www.onclive.com/view/updated...
Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC | OncLive
Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving considerations for treatment navigation in EGFR-mutant NSCLC.
www.onclive.com
December 22, 2025 at 6:12 PM
onclive.bsky.social
China’s NMPA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
#scmsm #oncology
www.onclive.com/view/china-s...
China’s NMPA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor | OncLive
The NMPA of China has approved pimicotinib, a CSF-1R inhibitor, for the treatment of adults with symptomatic TGCT.
www.onclive.com
December 22, 2025 at 5:33 PM
onclive.bsky.social
Small Team, Big Impact: Automation Helps Relieve Symptoms to Keep Cancer Patients Out of the ER
@mayoclinic.org #oncology
www.onclive.com/view/small-t...
Small Team, Big Impact: Automation Helps Relieve Symptoms to Keep Cancer Patients Out of the ER | OncLive
Patients were able to better manage symptoms with digital check-ins and remote care according to researchers at the Mayo Clinic.
www.onclive.com
December 22, 2025 at 5:17 PM
onclive.bsky.social
BREAKING 🚨: @fda.gov Approves Subcutaneous Mosunetuzumab for R/R Follicular Lymphoma

Learn more: www.onclive.com/view/fda-app...

#lymsm #oncology #FDAapproved
December 22, 2025 at 2:24 PM
onclive.bsky.social
This week’s #OncFive 5⃣:

✅ @fda.gov clears T-DXd combo in HER2+ breast cancer
💉 SC amivantamab approved for EGFR+ NSCLC
🧬 Rucaparib cleared in BRCA+ mCRPC
🏆 Priority voucher for teclistamab combo in myeloma
🚻 Periop EV combo meets EFS/OS in MIBC

🔗: www.onclive.com/view/the-onc...
December 21, 2025 at 12:40 AM
onclive.bsky.social
Analysis Sheds Light on Dosing Patterns of Ponatinib in Patients With CP-CML in the United States @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/analysi...
Analysis Sheds Light on Dosing Patterns of Ponatinib in Patients With CP-CML in the United States | OncLive
Only 13% of US patients with CP-CML received FDA-recommended ponatinib dosing, highlighting gaps in dose optimization and the need for education.
www.onclive.com
December 20, 2025 at 11:42 PM
onclive.bsky.social
Disease Status and Tumor Burden Do Not Affect CRS Incidence With Elranatamab Use in Myeloma @ash.hematology.org #ASH25 #mmsm #hematology
www.onclive.com/view/disease...
Disease Status and Tumor Burden Do Not Affect CRS Incidence With Elranatamab Use in Myeloma | OncLive
Tumor burden and disease status were not correlated with CRS risk or severity in newly diagnosed, relapsed/refractory myeloma managed with elranatamab.
www.onclive.com
December 19, 2025 at 7:43 PM
onclive.bsky.social
China’s NMPA Accepts New Drug Application for Tinengotinib Tablets for Advanced Cholangiocarcinoma #oncology www.onclive.com/view/china-s...
China’s NMPA Accepts New Drug Application for Tinengotinib Tablets for Advanced Cholangiocarcinoma | OncLive
The NMPA has accepted a new drug application for tinengotinib tablets for the treatment of patients with pretreated advanced/metastatic cholangiocarcinoma.
www.onclive.com
December 19, 2025 at 6:42 PM